文献速递前列腺癌

前列腺癌筛查与治疗的演变与未来方向

Prostate cancer screening and treatment: where have we come from and where are we going?
PubMed 文献 · BJU Int · 2020-07-27

本文回顾了前列腺癌诊断与治疗的演变,总结了三大筛查试验和三大治疗试验的长期结果。PSA检测可发现临床显著前列腺癌并带来分期迁移,但主要检出低级别惰性病变;根治性前列腺切除主要使<65岁中级别患者获益,高级别癌常进展。结论是PSA筛查策略应从早期发现所有癌转向识别可能携带临床显著疾病者。

要点

  • PSA检测带来分期迁移,与前列腺癌死亡率下降可能相关。
  • PSA筛查主要检出低级别惰性癌,导致过度诊断。
  • 根治性前列腺切除主要使<65岁中级别患者获益。

核心结论

  • 当前以早期发现所有前列腺癌为目的的PSA检测策略是错误的,应转向识别可能携带临床显著疾病者。

研究设计与样本

  • 历史综述,总结三大筛查试验和三大治疗试验的发现与差异。

主要发现

  • PSA检测可识别临床显著前列腺癌,并产生显著分期迁移,可能是前列腺癌死亡率下降的原因。
  • PSA检测主要识别低级别、终生不太可能进展的疾病,导致大量惰性癌诊断。
  • 根治性前列腺切除主要使<65岁、中级别疾病男性获益;低级别疾病获益太少,不足以对所有患者干预。
  • 高级别前列腺癌常尽管接受手术和放疗仍进展。

关键数值与推荐

  • 根治性前列腺切除主要使年龄<65岁、中级别疾病男性获益。

临床怎么用

  • PSA检测目标应从发现所有前列腺癌转向识别可能携带临床显著疾病者,这些男性可能从早期诊断和干预(包括广泛转移前更早使用抗雄激素治疗)中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the current prostate cancer screening and treatment paradigm in light of recently published long-term results of major screening and treatment trials. METHODS: Historical review of the evolution of the diagnosis and treatment of prostate cancer followed by a detailed summary of the findings and differences among the three major screening trials and the three major treatment trials. RESULTS: Prostate-specific antigen (PSA) testing can identify clinically significant prostate cancer and has produced a significant stage shift and is the likely explanation for the decline in prostate cancer mortality. Unfortunately, PSA testing predominantly identifies low-grade disease that is unlikely to progress during a patient's lifetime leading to substantial diagnosis of indolent disease. Treatment with radical prostatectomy (RP) appears to benefit primarily younger men (aged <65 years) with intermediate-grade disease. Too few men with low-grade disease benefit from RP to justify intervening in all. Unfortunately, high-grade prostate cancer often progresses despite surgery and radiation. CONCLUSION: The primary PSA testing paradigm is wrong. Rather than attempting to identify all prostate cancers as early as possible, testing objectives should shift towards identifying men likely to harbour clinically significant disease. These are the men who appear to benefit from early diagnosis and intervention, including the earlier use of antiandrogen therapy prior to widespread metastases.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Albertsen PC. Prostate cancer screening and treatment: where have we come from and where are we going? BJU Int. 2020. PMID: 32715604. doi:10.1111/bju.15153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。